UpdateUnlabelled: This article reports on recent advances on metastatic breast cancer. Detection, prognostic factors, predictors of response to therapy and therapy, with particular regard to targeted therapies, were examined. Detection: Unlike current guidelines that yet do not routinely recommend ...
Dr Jhaveri on the Rationale for the ELAINE-3 Trial in ESR1-Mutant ER+/HER2– Breast Cancer ESR1 Coalteration Treatment Resistance Does Not Impact Lasofoxifene/Abemaciclib Efficacy in ESR1+ Metastatic Breast Cancer Quality of Life, Toxicity Weighed Most by Patients When Choosing Metastatic Breast Cance...
At ESMO 2024, a host of significant abstracts will be presented, highlighting cutting-edge advancements in breast cancer treatment. From pivotal Phase III trials to novel therapeutic approaches, the conference will showcase groundbreaking data across various settings, including early and advanced/metastat...
EP: 1.Treatment Options in HER2-Positive Metastatic Breast Cancer EP: 2.Tucatinib for HER2-Positive Metastatic Breast Cancer EP: 3.Updated Results from HER2CLIMB and Tucatinib Use in Patient Subgroups EP: 4.Adverse Events in HER2-Positive Metastatic Breast Cancer Treatment Now Viewing EP: 5.Treat...
As therapeutic options have multiplied, chemotherapy for metastatic breast cancer (MBC) has become increasingly complex. Furthermore, advances in the treatment of early-stage breast cancer, in particular the development of taxane-based regimens, have led to increased use of adjuvant chemotherapy. As ...
MARGENZA is a prescription medicine approved for use in combination with chemotherapy for the treatment of adult patients with metastatic HER2+ breast cancer.
The present invention concerns treatment of previously untreated HER2-positive metastatic breast cancer with a combination of a growth inhibitory HER2 antibody, a HER2 dimerization inhibitor antibody and a taxane. In particular, the invention concerns the treatment of HER2-positive metastatic breast cancer...
" and perhaps most importantly by the consolidation of a new clinical category, HER2-low, which represents a more nuanced picture in the treatment of metastatic breast cancer. In the revised scheme, a subgroup of patients previously considered as HER2-negative are now redefined as an autonomous ...
Recent developments in treatment stratification for metastatic breast cancer.选择语言:从 到 翻译结果1翻译结果2 翻译结果3翻译结果4翻译结果5 翻译结果1复制译文编辑译文朗读译文返回顶部 在分层治疗转移性乳腺癌的近期发展。 翻译结果2复制译文编辑译文朗读译文返回顶部 在转移性的乳腺癌的治疗使成层的最近的发展...
Someone asked about treatment options for men with metastatic breast cancer. Dr. Gogineni do you want to maybe take a stab at that?Gogineni: Sure. You know, generally speaking, most of the time when a male is just diagnosed with breast cancer, it's usually going to be...